<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0707245490
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LISINO 20MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LISINOPRIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lisino&trade; contains a medicine called lisinopril. This belongs to a group of medicines<br />called ACE inhibitors.<br />Lisino&trade; can be used for the following conditions:<br />&bull; To treat high blood pressure (hypertension).<br />&bull; To treat heart failure.<br />&bull; If you have recently had a heart attack (myocardial infarction).<br />&bull; To treat kidney problems caused by Type II diabetes in people with high blood<br />pressure.<br />Lisino&trade; works by making your blood vessels widen. This helps to lower your blood<br />pressure. It also makes it easier for your heart to pump blood to all parts of your body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Lisino&trade; if:<br />&bull; You are allergic (hypersensitive) to lisinopril or any of the other ingredients of LisinoTM<br />(listed in Section 6: Further information).<br />&bull; You have ever had an allergic reaction to another ACE inhibitor medicine. The allergic<br />reaction may have caused swelling of the hands, feet, ankles, face, lips, tongue or throat.<br />It may also have made it difficult to swallow or breathe (angioedema).<br />&bull; A member of your family has had severe allergic reactions (angioedema) to an ACE<br />inhibitor or you have had severe allergic reactions (angioedema) without a known cause.<br />&bull; If you are more than 3 months pregnant. (It is also better to avoid LisinoTM in early<br />pregnancy - see Pregnancy section).<br />&bull; If you are taking a blood pressure medicine containing aliskiren and you have diabetes.<br />&bull; If you are taking a blood pressure medicine containing aliskiren and you have kidney<br />problems.<br />Do not take Lisino&trade; if any of the above applies to you. If you are not sure, talk to your<br />doctor or pharmacist before taking Lisino&trade;.<br />If you develop a dry cough which is persistent for a long time after starting treatment with<br />Lisino&trade;, talk to your doctor.<br />Take special care with Lisino&trade;<br />Check with your doctor or pharmacist before taking Lisino&trade; if:<br />&bull; You have a narrowing (stenosis) of the aorta (an artery in your heart) or a narrowing of<br />the heart valves (mitral valves).<br />&bull; You have a narrowing (stenosis) of the kidney artery.<br />&bull; You have an increase in the thickness of the heart muscle (known as hypertrophic<br />cardiomyopathy).<br />&bull; You have problems with your blood vessels (collagen vascular disease).<br />&bull; You have low blood pressure. You may notice this as feeling dizzy or light-headed,<br />especially when standing up.<br />&bull; You have kidney problems or you are having kidney dialysis.<br />&bull; You have liver problems.<br />&bull; You have diabetes.<br />&bull; You have recently had diarrhoea or vomiting (being sick).<br />&bull; Your doctor has told you to control the amount of salt in your diet.<br />&bull; You have high levels of cholesterol and you are having a treatment called &lsquo;LDL<br />apheresis&rsquo;.<br />&bull; You must tell your doctor if you think you are (or might become) pregnant. LisinoTM is<br />not recommended in early pregnancy, and must not be taken if you are more than 3<br />months pregnant, as it may cause serious harm to your baby if used at that stage (see<br />Pregnancy section).<br />&bull; You are of black origin as Lisino&trade; may be less effective. You may also more readily get<br />the side effect &lsquo;angioedema&rsquo; (a severe allergic reaction).<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist<br />before taking Lisino&trade;.<br />Combination therapy of ACEI and ARB drugs may cause an increased risk of<br />hyperkalemia, worsening of kidney function and hypotension. Therefore, this<br />combination should not be used, especially in patients with renal impairment.<br />Treatment for allergies such as insect stings<br />Tell your doctor if you are having or are going to have treatment to lower the effects of an<br />allergy such as insect stings (desensitisation treatment). If you take Lisino&trade; while you are<br />having this treatment, it may cause a severe allergic reaction.<br />Operations<br />If you are going to have an operation (including dental surgery) tell the doctor or dentist<br />that you are taking Lisino&trade;. This is because you can get low blood pressure (hypotension)<br />if you are given certain local or general anaesthetics while you are taking Lisino&trade;.<br />Taking other medicines<br />Tell your doctor if you are taking, or have recently taken, any other medicines. This<br />includes medicines that you buy without a prescription. This is because Lisino&trade; can affect<br />the way some medicines work and some medicines can have an effect on<br />Lisino&trade;.<br />In particular, tell your doctor or pharmacist if you are taking any of the following<br />medicines:<br />&bull; Other medicines to help lower your blood pressure.<br />&bull; Aliskiren containing medicines (for treatment of high blood pressure).<br />&bull; Water tablets (diuretic medicines).<br />&bull; Medicines to break up blood clots (usually given in hospital).<br />&bull; Beta-blocker medicines, such as atenolol and propranolol.<br />&bull; Nitrate medicines (for heart problems).<br />&bull; Non-steroidal anti-inflammatory drugs (NSAIDs) used to treat pain and arthritis.<br />&bull; Aspirin (Acetylsalicylic acid), if you are taking more than 3 grams each day.<br />&bull; Medicines for depression and for mental problems, including lithium.<br />&bull; Potassium tablets or salt substitutes that have potassium in them.<br />&bull; Insulin or medicines that you take by mouth for diabetes.<br />&bull; Medicines used to treat asthma.<br />&bull; Medicines to treat nose or sinus congestion or other cold remedies (including those you<br />can buy in the pharmacy).<br />&bull; Medicines to suppress the body&rsquo;s immune response (immunosuppressants).<br />&bull; Allopurinol (for gout).<br />&bull; Procainamide (for heart beat problems).<br />&bull; Medicines that contain gold, such as sodium aurothiomalate, which may be given to you<br />as an injection.<br />Pregnancy and breast-feeding<br />Pregnancy:<br />You must tell your doctor if you think you are (or might become) pregnant. Your doctor<br />will normally advise you to stop taking Lisino&trade; before you become pregnant or as soon as<br />you know you are pregnant and will advise you to take another medicine instead of<br />Lisino&trade;. Lisino&trade; is not recommended in early pregnancy, and must not be taken when<br />more than 3 months pregnant, as it may cause serious harm to your baby if used after the<br />third month of pregnancy.<br />Breast-feeding:<br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Lisino&trade; is not<br />recommended for mothers who are breast-feeding, and your doctor may choose another<br />treatment for you if you wish to breast-feed, especially if your baby is newborn, or was<br />born prematurely.<br />Driving and using machines<br />&bull; Some people feel dizzy or tired when taking this medicine. If this happens to you, do not<br />drive or use any tools or machines.<br />&bull; You must wait to see how your medicine affects you before trying these activities.<br />Important information about the ingredients of Lisino&trade;<br />These tablets contain lactose. If you have an intolerance to some sugars, please speak to<br />your pharmacist or doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Lisino&trade; exactly as your doctor has told you. You should check with your<br />doctor or pharmacist if you are not sure.<br />Once you have started taking Lisino&trade; your doctor may take blood tests. Your doctor may<br />then adjust your dose so you take the right amount of medicine for you.<br />Taking your medicine<br />&bull; Swallow the tablet with a drink of water.<br />&bull; Try to take your tablets at the same time each day. It does not matter if you take Lisino&trade;<br />before or after food.<br />&bull; Keep taking Lisino&trade; for as long as your doctor tells you to, it is a long term treatment.<br />It is important to keep taking LisinoTM every day.<br />Taking your first dose<br />&bull; Take special care when you have your first dose of Lisino&trade; or if your dose is increased.<br />It may cause a greater fall in blood pressure than later doses.<br />&bull; This may make you feel dizzy or light-headed. If this happens, it may help to lie down.<br />If you are concerned, please talk to your doctor as soon as possible.<br />Adults<br />Your dose depends on your medical condition and whether you are taking any other<br />medicines. Your doctor will tell you how many tablets to take each day. Check with your<br />doctor or pharmacist if you are unsure.<br />For high blood pressure<br />&bull; The recommended starting dose is 10 mg once a day.<br />&bull; The usual long-term dose is 20 mg once a day.<br />For heart failure<br />&bull; The recommended starting dose is 2.5 mg once a day.<br />&bull; The long-term dose is 5 to 35 mg once a day.<br />After a heart attack<br />&bull; The recommended starting dose is 5 mg within 24 hours of your attack and 5 mg one<br />day later.<br />&bull; The usual long-term dose is 10 mg once a day.<br />For kidney problems caused by diabetes<br />&bull; The recommended dose is either 10 mg or 20 mg once a day.<br />If you are elderly, have kidney problems or are taking diuretic medicines your doctor may<br />give you a lower dose than the usual dose.<br />Children and adolescents (6 to 16 years old) with high blood pressure<br />&bull; LisinoTM is not recommended for children under 6 years or in any children with severe<br />kidney problems.<br />&bull; The doctor will work out the correct dose for your child. The dose depends on the<br />child&rsquo;s body weight.<br />&bull; For children who weigh between 20 kg and 50 kg, the recommended starting dose is<br />2.5 mg once a day.</p><p>&bull; For children who weigh more than 50 kg, the recommended starting dose is 5 mg once<br />a day.<br />If you take more Lisino&trade; than you should<br />If you take more Lisino&trade; than prescribed by your doctor, talk to a doctor or go to a<br />hospital immediately. The following effects are most likely to happen: Dizziness,<br />palpitations.<br />If you forget to take Lisino&trade;<br />&bull; If you forget to take a dose, take it as soon as you remember. However, if it is nearly<br />time for the next dose, skip the missed dose.<br />&bull; Do not take a double dose to make up for a forgotten dose.<br />If you stop taking Lisino&trade;<br />Do not stop taking your tablets, even if you are feeling well, unless your doctor tells<br />you to.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, This medicine can cause side effects, although not everybody gets<br />them.<br />If you experience any of the following reactions, stop taking Lisino&trade; and see your doctor<br />immediately:<br />&bull; Severe allergic reactions (rare, affects 1 to 10 users in 10,000). The signs may include<br />sudden onset of:<br />- Swelling of your face, lips, tongue or throat. This may make it difficult to swallow.<br />- Severe or sudden swelling of your hands, feet and ankles.<br />- Difficulty breathing.<br />- Severe itching of the skin (with raised lumps).<br />&bull; Severe skin disorders, like a sudden, unexpected rash or burning, red or peeling skin<br />(very rare, affects less than 1 user in 10,000).<br />&bull; An infection with symptoms such as fever and serious deterioration of your general<br />condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or<br />urinary problems (very rare, affects less than 1 user in 10,000).<br />Other possible side effects:<br />Common (affects 1 to 10 users in 100)<br />&bull; Headache.<br />&bull; Feeling dizzy or light-headed, especially if you stand up quickly.<br />&bull; Diarrhoea.<br />&bull; A dry cough that does not go away.<br />&bull; Being sick (vomiting).<br />&bull; Kidney problems (shown in a blood test).<br />Uncommon (affects 1 to 10 users in 1,000)<br />&bull; Mood changes.<br />&bull; Change of colour in your fingers or toes (pale blue followed by redness) or numbness or<br />tingling in your fingers or toes.<br />&bull; Changes in the way things taste.<br />&bull; Feeling sleepy.<br />&bull; Spinning feeling (vertigo).<br />&bull; Having difficulty sleeping.<br />&bull; Stroke.<br />&bull; Fast heart beat.<br />&bull; Runny nose.<br />&bull; Feeling sick (nausea).<br />&bull; Stomach pain or indigestion.<br />&bull; Skin rash or itching.<br />&bull; Being unable to get an erection (impotence).<br />&bull; Feeling tired or feeling weak (loss of strength).<br />&bull; A very big drop in blood pressure may happen in people with the following conditions:<br />coronary heart disease; narrowing of the aorta (a heart artery), kidney artery or heart<br />valves; an increase in the thickness of the heart muscle. If this happens to you, you may<br />feel dizzy or light-headed, especially if you stand up quickly.<br />&bull; Changes in blood tests that show how well your liver and kidneys are working.<br />&bull; Heart attack.<br />&bull; Seen and/or heard hallucinations.<br />Rare (affects 1 to 10 users in 10,000)<br />&bull; Feeling confused.<br />&bull; A lumpy rash (hives).<br />&bull; Dry mouth.<br />&bull; Hair loss.<br />&bull; Psoriasis (a skin problem).<br />&bull; Changes in the way things smell.<br />&bull; Development of breasts in men.<br />&bull; Changes to some of the cells or other parts of your blood. Your doctor may take blood<br />samples from time to time to check whether LisinoTM has had any effect on your blood.<br />The signs may include feeling tired, pale skin, a sore throat, high temperature (fever), joint<br />and muscle pains, swelling of the joints or glands, or sensitivity to sunlight.<br />&bull; Low levels of sodium in your blood (the symptoms may be tiredness, headache, nausea,<br />vomiting).<br />&bull; Sudden renal failure.<br />Very rare (affect less than 1 user in 10,000)<br />&bull; Sinusitis (a feeling of pain and fullness behind your cheeks and eyes).<br />&bull; Wheezing.<br />&bull; Low levels of sugar in your blood (hypoglycaemia). The signs may include feeling<br />hungry or weak, sweating and a fast heart beat.<br />&bull; Inflammation of the lungs. The signs include cough, feeling short of breath and high<br />temperature (fever).<br />&bull; Yellowing of the skin or the whites of the eyes (jaundice).<br />&bull; Inflammation of the liver. This can cause loss of appetite, yellowing of the skin and eyes,<br />and dark coloured urine.<br />&bull; Inflammation of the pancreas. This causes moderate to severe pain in the stomach.<br />&bull; Severe skin disorders. The symptoms include redness, blistering and peeling.<br />&bull; Sweating.<br />&bull; Passing less water (urine) than normal or passing no water.<br />&bull; Liver failure.<br />&bull; Lumps.<br />&bull; Inflamed gut.<br />Not known (frequency cannot be estimated from available data)<br />&bull; Symptoms of depression.<br />&bull; Fainting.<br />Side effects in children appear to be comparable to those seen in adults.<br />If any of the side effects get serious, or if you notice any side effects not listed in this<br />leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &ordm;C.<br />&bull; Do not use after the expiry date (EXP) which is stated on the blister strip and the<br />carton.<br />&bull; Medicines should not be disposed of via waste water or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. This will help to protect<br />the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lisinopril (as dihydrate).<br />The other ingredients are dibasic calcium phosphate dihydrate, mannitol,<br />pregelatinized starch, maize starch, colloidal silicon dioxide and magnesium stearate.<br />In addition Lisino tablets 20mg contain iron oxide yellow.<br />Lisino&trade; is supplied in 3 strengths containing 5 mg, 10 mg or 20 mg of lisinopril (as<br />dihydrate).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lisino™ 5mg Tablets: White to off white, round, biconvex uncoated tablets engraved
with 'JP 40' on one side and plain on the other side.
Lisino™ 10mg Tablets: White to off white, round, biconvex uncoated tablets engraved
with 'JP 41' on one side and plain on the other side.
Lisino™ 20mg Tablets: Light yellow, round, biconvex uncoated tablets engraved with
'JP 42' on one side and plain on the other side.
Lisino™ Tablets availble in 5 mg,10 mg & 20 mg tablets in boxes of 30 tablets each.
Not all packs may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111 Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />Please report adverse drug events to:<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12505601 - Rev. 03/15-08-2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ليزينو&trade; يحتوى على ليزينوبريل و هو دواء ينتمى إلى مجموعة من الأدوية تسمى مثبطات الإنزيم<br />.(ACE inhibitors ) ا لمحول للأنجيوتنسين<br />يستخدم فى الحالات التالية:&nbsp;<br />&bull; لعلاج ضغط الدم المرتفع.<br />&bull; لعلاج قصور القلب.<br />&bull; إذا عانيت مؤخرا من أزمة قلبية (احتشاء القلب).<br />&bull; لعلاج مشاكل الكلى الناتجة عن الإصابة بداء السكرى من النوع الثانى لدى الأشخاص الذين يعانون من<br />ارتفاع ضغط الدم.<br />يعمل ليزينو&trade; على توسعة الأوعية الدموية مما يساعد فى خفض ضغط الدم .كما إنه يسهل على القلب<br />عملية ضخ الدم إلى جميع أجزاء الجسم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول ليزينو &trade; فى الحالات الآتية:&bull; إذا كانت لديك حساسية مفرطة لليزينوبريل أو أى من المكونات الأخرى لهذا الدواء و المذكورة فى الجزء<br />رقم ٦ من هذه النشرة.<br />&bull; إذا عانيت من قبل من رد فعل تحسسى لأى دواء آخر من مثبطات الإنزيم المحول للأنجيوتنسين. رد الفعل<br />التحسسى يسبب تورم اليدين، القدمين، الكاحلين، الوجه، الشفتين، اللسان أو الحلق .من الممكن أيضا أن<br />يسبب صعوبة فى التنفس أو البلع (وذمة وعائية).<br />&bull; إذا كان أحد أفراد عائلتك يعانى من حساسية شديدة ( وذمة وعائية) لأى دواء من مثبطات الإنزيم المحول<br />للأنجيوتنسين أو إذا كنت قد عانيت من رد فعل تحسسى شديد ( وذمة وعائية) بدون وجود سبب معروف.<br />فى أشهر الحمل الأولى &ndash; انظر إلى &trade; &bull; بعد الشهر الثالث فى الحمل (من الأفضل أيضاً تجنب استخدام ليزينو<br />الجزء الخاص بالحمل فى هذه النشرة).<br />&bull; إذا كنت تأخذ أدوية ضغط الدم التي تحتوي على أليسكيرين وكان لديك مرض السكري.<br />&bull; إذا كنت تأخذ أدوية ضغط الدم التي تحتوي على أليسكيرين وكان لديك مشاكل فى الكلى.<br />إذا انطبقت عليك إحدى الحالات المذكورة بالأعلى . إذا كنت غير متأكد، تحدث مع الطبيب &trade; لا تتناول ليزينو<br />&trade; أو الصيدلى قبل البدء فى تناول ليزينو<br />يرجى اخبار الطبيب. &trade; إذا عانيت من سعال مستمر لفترة طويلة بعد بدء العلاج ليزينو<br />فى الحالات الآتية: &trade; أعط عناية خاصة عند تناول ليزينو<br />إذا كنت تعانى من: &trade; تحقق من الطبيب أو الصيدلى قبل بدء العلاج ليزينو<br />&bull; ضيق فى الشريان الأورطى أو ضيق فى صمامات القلب.<br />&bull; ضيق فى شريان الكلية.<br />&bull; زيادة فى سمك عضلة القلب المعروف باسم إعتلال عضلة القلب الضخامى.<br />&bull; مشكلة فى الأوعية الدموية مثل الداء الوعائى الكولاجينى.<br />&bull; انخفاض ضغط الدم ، من الممكن أن تلاحظ هذا فى صورة الشعور بالدوار أو الدوخة خاصة عند الوقوف.<br />&bull; مشاكل فى الكلى أو تجرى غسيل كلوى.<br />&bull; مشاكل فى الكبد.<br />&bull; داء السكرى.<br />&bull; عانيت من إسهال أو قىء مؤخرا.<br />&bull; إذا أخبرك طبيبك بأنه يجب عليك التحكم بكمية الملح فى طعمك.<br />&bull; إرتفاع مستوى الكوليسترول فى دمك و تتم معالجتك عن طريق ما يسمى ب &quot; فصادَة الليبوبروتين ذو<br />الكثافة الشحمية المنخفضة.&quot;<br />فى أشهر &trade; &bull; يجب عليكِ اخبار الطبيب إذا كنتِ حاملا أو تشكين فى كونك حاملا .لا ينصح باستخدام ليزينو<br />الحمل الأولى و يحظر استخدامه بعد الشهر الثالث من الحمل لأنه من الممكن أن يسبب ضرر خطير للجنين<br />إذا استخدم فى هذه المرحلة (انظر إلى الجزء الخاص بالحمل فى هذه النشرة).<br />قد يصبح أقل فاعلية فى هذه الحالة .كما قد تصبح أكثر &trade; &bull; إذا كنت من أصل ذوى البشرة السمراء لأن ليزينو<br />عرضة للإصابة بالأثر الجانبى&quot; الوذمة الوعائية &quot;و هو رد فعل تحسسى شديد.<br />إذا كنت غير متأكد إذا كنت تعانى من إحدى الحالات السابق ذكرها ، تحدث مع الطبيب أو الصيدلى قبل أن<br />&trade; تأخذ ليزينو<br />وأدوية مثبطات مستقبلات ACEI الجمع بين العلاج بأدوية مثبطات الإنزيم المحول للأنجيوتنسين<br />قد يسبب زيادة خطرفرط بوتاسيوم الدم، وتدهور وظائف الكلى وانخفاض ضغط الدم. ARBI الأنچيوتنسين<br />لذلك، لا ينبغي أن يستخدم هذا الجمع، وخصوصا في المرضى الذين يعانون من القصور الكلوي.<br />معالجة الحساسية مثل التى تسببها لسعات الحشرات<br />اخبر طبيبك إذا كنت تتناول أو سوف تتناول علاج ما للحد من تأثيرات الحساسية مثل التى تسببها لسعات<br />الحشرات (علاج منع التحسس).<br />أثناء تلقيك هذا العلاج من الممكن أن يسبب لك رد فعل تحسسى خطير. &trade; إذا كنت تتناول ليزينو<br />إجراء العمليات الجراحية<br />و ذلك لأن &trade; إذا كنت سوف تجرى عملية جراحية ما يرجى اخبار الطبيب أو طبيب الأسنان أنك تتناول ليزينو<br />من الممكن أن تصاب بإنخفاض فى ضغط الدم عند تلقيك نوع معين من أنواع التخدير الموضعى أو الكلى.<br />تناول أدوية أخرى<br />يرجى إخبار الطبيب أو الصيدلى إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى .هذا يشمل الأدوية التى<br />قد يؤثر على طريقة عمل بعض الأدوية ، أيضا بعض &trade; يمكنك شراؤها بدون تذكرة طبية .ذلك لأن ليزينو<br />&trade;. الأدوية قد تؤثر على طريقة عمل ليزينو<br />يرجى اخبار الطبيب أو الصيدلى فى حالة تناولك أى من الأدوية التالية:<br />&bull; أى دواء آخر يستخدم لخفض ضغط الدم.<br />&bull; الأدوية التي تحتوي على أليسكيرين (لعلاج ارتفاع ضغط الدم).<br />&bull; الأدوية المدرّة للبول.<br />&bull; الأدوية المضادة للتجلط (عادة تعطى فى المستشفي).<br />&bull; حاصرات بيتا مثل أتينولول و بروبرانولول.<br />&bull; الأدوية المحتوية على النيترات و التى تستخدم لعلاج مشاكل القلب.<br />&bull; مضادات الإلتهاب غير الإستيرودية التى تستخدم لتسكين الألم وعلاج إلتهاب المفاصل.<br />&bull; إذا كنت تأخذ أكثر من ۳ جرامات من (الاسبرين حمض الأسيتيل ساليسيلك) يوميا.<br />&bull; أدوية علاج الإكتئاب و الإضطرابات النفسية و منها الليثيوم.<br />&bull; أقراص البوتاسيوم أو بدائل الملح المحتوية على البوتاسيوم.<br />&bull; الأنسولين أو أدوية علاج مرض السكرى التى تؤخذ عن طريق الفم.<br />&bull; أدوية علاج الربو.<br />&bull; أدوية علاج التهاب احتقان الأنف أو الجيوب الأنفية أو أدوية البرد الأخرى ( بما فيها الأدوية التى يمكن<br />شرائها بدون وصفة طبية ).<br />&bull; الأدوية المثبطة للمناعة.<br />&bull; ألوبيورينول المستخدم لعلاج النقرص.<br />&bull; بروكيناميد المستخدم لعلاج إضطرابات ضربات القلب.<br />&bull; الأدوية المحتوية على الذهب مثل صوديوم أوروثيومالات الذى يعطى عن طريق الحقن.<br />الحمل و الرضاعة<br />الحمل<br />يرجى اخبار طبيبك إذا كنتِ تعتقدين انك حاملا أو قد تصبحين حاملا . بطبيعة الحال سوف ينصحك طبيبك<br />قبل أن تصبحين حاملا أو بمجرد علمك بانك حاملا و سوف ينصحك بتناول دواء آخر &trade; بوقف تناول ليزينو<br />&trade; بدلا من ليزينو<br />فى أشهر الحمل الأولى و يحظر استخدامه بعد الشهر الثالث من الحمل لأنه من &trade; لا ينصح باستخدام ليزينو<br />الممكن أن يسبب ضرر خطير للجنين إذا استخدم فى هذه المرحلة.<br />الرضاعة<br />يرجى اخبار طبيبك إذا كنت ترضعين طبيعيا أو على وشك البدء فى الرضاعة الطبيعية.<br />لدى السيدات المرضعات و قد يختار طبيبك دواء آخر إذا كنت تريدين أن &trade; لا ينصح باستخدام ليزينو<br />ترضعى طفلك طبيعيا.<br />قيادة المركبات و تشغيل الآلات<br />&bull; قد يشعر بعض الأشخاص بالدوار أو التعب أثناء تناول هذا الدواء .لو حدث هذا لك ، لا تقد و لا تستخدم أى<br />آلات أو أدوات.<br />&bull; يجب أن تنتظر لتعرف تأثير هذا الدواء عليك قبل قيامك بهذه الأنشطة.<br />&trade; معلومة هامة عن بعض المكونات الموجودة فى أقراص ليزينو<br />أحد مكونات هذا الدواء يحتوى على اللاكتوز . إذا قيل لك أنه لا يمكنك هضم أو تحمل بعض السكريات ،<br />&trade; أخبر طبيبك أوالصيدلي بهذا قبل البدء فى تناول ليزينو</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كما أخبرك طبيبك تماما. يجب عليك مراجعة طبيبك أو الصيدلى الخاص بك إذا كنت &trade; قم دائما بتناول ليزينو<br />غير متأكد من طريقة الاستخدام.<br />سوف يطلب منك طبيبك القيام ببعض فحوصات الدم. &trade; بمجرد بدء تناول ليزينو<br />سوف يقوم طبيبك بعد ذلك بتعديل جرعتك حتى تحصل على كمية الدواء المناسبة لك.<br />&trade; كيف تتناول ليزينو<br />&bull; قم ببلع القرص مع شربة ماء.<br />قبل الأكل أو بعده. TM &bull; حاول أن تتناول أقراصك فى نفس الوقت يومياً .يمكن أن تناول أقراص ليزينو<br />لأطول فترة ممكنة فهو علاج طويل الأمد . من المهم أن تحافظ على تناول &trade; &bull; حافظ على تناول ليزينو<br />يومياً. &trade; ليزينو<br />تناول الجرعة الأولى<br />أو عند زيادة الجرعة لأنه من الممكن أن تسبب &trade; &bull; أعط عناية خاصة عند تناولك الجرعة الأولى من ليزينو<br />انخفاض فى ضغط الدم يفوق الجرعات السابقة .هذا قد يشعرك بالدوار ، عند حدوث هذا ، فإن الإستلقاء قد<br />يساعدك على التخلص من هذا الدوار .إذا لم تتحسن يرجى الإتصال بطبيبك فى أسرع وقت ممكن.<br />الكبار<br />جرعتك تعتمد على حالتك الطبية و إذا كنت تتناول أى أدوية أخرى .سوف يخبرك طبيبك بكمية الأقراص<br />التى يجب عليك أن تتناولها يومياً .تحقق من الطبيب أو الصيدلى إذا كنت غير متأكد من جرعتك.<br />لعلاج ضغط الدم المرتفع<br />&bull; الجرعة الأولية الموصى بها هى ۱۰ ملجم مرة يومياً.<br />&bull; الجرعة طويلة الأمد المعتادة هى ۲۰ ملجم مرة يومياً.<br />لعلاج قصور القلب<br />&bull; الجرعةالأولية الموصى بها هى ۲٫٥ ملجم مرة يومياً.<br />&bull; الجرعة طويلة الأمد المعتادة هى ٥ إلى ۳٥ ملجم مرة يومياً.<br />بعد الإصابة بأزمة قلبية<br />&bull; الجرعةالأولية الموصى بها هى ٥ ملجم خلال ۲٤ ساعة من أزمتك القلبية و ٥ ملجم لمدة يوم آخر.<br />&bull; الجرعة طويلة الأمد المعتادة هى ۱۰ ملجم مرة يومياً.<br />لعلاج مشاكل الكلى الناتجة عن الإصابة بمرض السكرى<br />&bull; الجرعة الموصى بها إما ۱۰ ملجم أو ۲۰ ملجم مرة يومياً.<br />إذا كنت من المسنين و تعانى من مشاكل فى الكلى أو تتناول أدوية مدرّة للبول ، من الممكن أن يعطيك طبيبك<br />جرعة أقل من الجرعة المعتادة.<br />الأطفال و المراهقين(من ٦ إلى ۱٦ عام)المصابون بإرتفاع ضغط الدم<br />فى الأطفال أقل من ٦ سنوات أو أى طفل يعانى من مشاكل شديدة فى الكلى. &trade; &bull; لا يوصى باستخدام ليزينو<br />&bull; سوف يقوم طبيبك بحساب الجرعة الصحيحة لطفلك بناءاً على وزن الطفل.</p><p>&bull; للأطفال الذين يزنون بين ۲۰ و ٥۰ كيلو جرام ، الجرعة الأولية الموصى بها هى ۲٫٥ ملجم مرة يومياً.<br />&bull; للأطفال الذين يزنون أكثر من ٥۰ كيلو جرام ، الجرعة الأولية الموصى بها هى ٥ ملجم مرة يومياً.<br />أكثر مما ينبغى: &trade; إذا كنت تناولت ليزينو<br />أكثر مما وصفه الطبيب ، تحدث إلى طبيبك أو اذهب إلى المستشفى على &trade; إذا كنت تناولت أقراص ليزينو<br />الفور. من المرجح حدوث التأثيرات التالية :الدوار و الخفقان.<br />&trade; إذا نسيت تناول ليزينو<br />تناول الجرعة بمجرد تذكرك .لكن إذا حان الوقت للجرعة التالية لا &trade; &bull; إذا نسيت تناول جرعة من ليزينو<br />تتناول الجرعة المنسية.<br />&bull; لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br />&trade; إذا توقفت عن تناول ليزينو<br />حتى إذا شعرت بالتحسن ، إلا إذا طلب منك طبيبك التوقف عن &trade; لا تتوقف أبدا عن تناول أقراص ليزينو<br />تناولها.<br />إذا كانت لديك أى أسئلة أخرى عن هذا الدواء ،اسأل الطبيب أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية ، من المحتمل ظهور أعراض جانبية مع هذا الدواء لكنها لا تصيب كل<br />الأشخاص.<br />و توجه إلى الطبيب على الفور إذا عانيت من إحدى الآثار الآتية: &trade; توقف عن تناول ليزينو<br />&bull; رد فعل تحسسى خطير ( أعراض جانبية نادرة ، تصيب ۱ إلى ۱۰ من ۱۰۰۰۰ شخص يستخدمون هذا<br />الدواء ) الأعراض تشمل شعور مفاجىء بما يلى:<br />&bull; تورم الوجه ،الشفتين ،اللسان أو الحلق مما يسبب صعوبة فى البلع.<br />&bull; تورم مفاجىء و شديد فى اليدين ،القدمين أو الكاحلين.<br />&bull; صعوبة فى التنفس.<br />&bull; حكة شديدة فى الجلد.<br />&bull; إضطرابات شديدة مفاجئة و غير متوقعة تصيب الجلد مثل طفح جلدى ، تحرُّق ، إحمرار أو تقشر فى الجلد.<br />&bull; عدوى لها أعراض مثل حمى مصحوبة بتدهور شديد فى حالتك الصحية العامة أو حمى مصحوبة بأعراض<br />العدوى الموضعية مثل إلتهاب الحلق/الحنجرة/الفم أو مشاكل فى الجهاز البولى (أعراض جانبية نادرة جدا،<br />تصيب أقل من ۱ من ۱۰۰۰۰ شخص يستخدمون هذا الدواء).<br />الآثار الجانبية المحتملة الأخرى:<br />أعراض جانبية شائعة (تصيب ۱ إلى ۱۰ من كل ۱۰۰ شخص يستخدمون هذا الدواء)<br />&bull; صداع.<br />&bull; الشعور بالدوار خاصة عند الوقوف بسرعة.<br />&bull; إسهال.<br />&bull; سعال جاف مستمر.<br />&bull; قىء.<br />&bull; مشاكل فى الكلى.<br />أعراض جانبية غير شائعة (تصيب ۱ إلى ۱۰ من كل ۱۰۰۰ شخص يستخدمون هذا الدواء)<br />&bull; تغيرات مزاجية.<br />&bull; تغير فى لون أصابع اليدين أو القدمين (تصبح زرقاء شاحبة ثم حمراء اللون) أو الشعور بوخز أو تنميل فى<br />أصابع اليدين أو القدمين.<br />&bull; تغير فى حاسة التذوق.<br />&bull; الشعور بالنعاس.<br />&bull; الشعور بالدوار.<br />&bull; وجود صعوبة فى النوم.<br />&bull; سكتة دماغية.<br />&bull; ضربات قلب سريعة.<br />&bull; سيلان الأنف.<br />&bull; غثيان.<br />&bull; ألم فى المعدة وعسر هضم.<br />&bull; طفح جلدى و حكة.<br />&bull; ضعف الإنتصاب (الضعف الجنسى).<br />&bull; الشعور بالتعب و الضعف.<br />&bull; إنخفاض شديد فى ضغط الدم لدى الأشخاص الذين يعانون من الحالات المرضية التالية: مرض القلب<br />التاجى ،ضيق الشريان التاجى ،ضيق فى شريان الكلية ،ضيق فى صمامات القلب ،زيادة فى سمك عضلة<br />القلب .عند حدوث هذا لك ، سوف تشعر بالدوار أو الدوخة خاصة عند الوقوف بصورة مفاجئة.<br />&bull; تغير فى نتائج فحوصات الدم التى توضح كيفية عمل الكبد و الكليتين.<br />&bull; أزمة قلبية.<br />&bull; هلاوس سمعية و / أو بصرية.<br />أعراض جانبية نادرة ( تصيب ۱ إلى ۱۰ من كل ۱۰۰۰۰ شخص يستخدمون هذا الدواء)<br />&bull; الشعور بالتشوش.<br />&bull; طفح جلدى عقدى.<br />&bull; جفاف الفم.<br />&bull; فقدان الشعر.<br />&bull; صدفية (مشكلة تصيب الجلد).<br />&bull; تغير فى حاسة الشم.<br />&bull; تضخم الثديين فى الرجال.<br />&bull; تغيرات فى بعض خلايا الدم و بعض أجزاء الجسم .قد يأخذ طبيبك عينات دم من وقت لآخر ليتحقق إذا كان<br />له أى تأثيرات على خلايا دمك . الأعراض تشمل الشعور بالتعب، جلد شاحب، حمى، آلام المفاصل &trade; ليزينو<br />و العضلات، تورم المفاصل أو الغدد أو الحساسية لأشعة الشمس.<br />&bull; إنخفاض مستوى الصوديوم فى الدم ، الأعراض تشمل إرهاق، صداع، غثيان وقىء.<br />&bull; قصور كلوى مفاجىء.<br />أعراض جانبية نادرة جدا (تصيب أقل من ۱ من كل ۱۰۰۰۰ شخص يستخدمون هذا الدواء)<br />&bull; إلتهاب الجيوب الأنفية (الشعور بألم و امتلاء خلف الخدين و العينين).<br />&bull; صفير الصدر عند التنفس.<br />&bull; إنخفاض مستوى السكر بالدم .الأعراض تشمل الشعور بالجوع أو الضعف، التعرق و ضربات قلب سريعة.<br />&bull; إلتهاب الرئتين .الأعراض تشمل كحة، ضيق فى التنفس و حمى.<br />&bull; إصفرار الجلد أو بياض العينين.<br />&bull; إلتهاب الكبد مما يسبب آلام معتدلة إلى حادة فى المعدة.<br />&bull; إضطرابات شديدة فى الجلد . الأعراض تشمل إحمرار، تقرح و تقشر الجلد.<br />&bull; تعرق.<br />&bull; إخراج كمية من البول أقل من المعتاد أو عدم إخراج البول.<br />&bull; قصور فى الكبد.<br />&bull; تكتلات فى الجلد.<br />&bull; إلتهاب الأمعاء.<br />أعراض جانبية غير معلوم مدى شيوعها<br />&bull; أعراض الإكتئاب.<br />&bull; فقدان الوعى.<br />الأعراض الجانبية فى الأطفال تكون مماثلة لتلك التى تحدث للكبار.<br />يرجى اخبار الطبيب أو الصيدلى إذا أصبحت أى من الأعراض السابقة خطيرة أو لاحظت ظهور أى<br />أعراض أخرى غير مذكورة فى هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيدا عن متناول و مرأى الأطفال.<br />&bull; يحفظ فى درجة حرارة لا تزيد عن ۳۰م&ordm;<br />&bull; لا تتناول أقراص ليزينو بعد انتهاء فترة صلاحيتها المكتوب على الشرائط وعلى العلبة.<br />&bull; اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها .لا ينبغي التخلص من الأدوية عبر<br />إلقائها فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لمادة الفعالة فى أقراص ليزينو هى ليزينوبريل (دايهايدرات) .<br />المكونات الأخرى :ثنائي القاعدة فوسفات الكالسيوم ثنائي الهيدرات، مانيتول، نشا بريجيلاتينيزد، نشا<br />&trade; الذرة، وثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم. بالإضافة لذلك تحتوي أقراص ليزينو<br />۲۰ ملجم علي أكسيد الحديد الأصفر.<br />ليزينو متوفر فى ثلاث تركيزات: ٥ ملجم، ۱۰ ملجم أو ۲۰ ملجم ليزينوبريل (دايهايدرات).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">ما هو شكل أقراص ليزينو<br />أقراص ليزينو ٥ ملجم: لونها أبيض إلى مائل للأبيض، دائرية، محدبة الوجهين غيرمغلفة، محفور على&nbsp;أحد الجانبين &quot;JP40&quot;<br />ومستوية علي الجانب الآخر.&nbsp;<br />أقراص ليزينو۱۰ ملجم: لونها أبيض إلى مائل للأبيض، دائرية، محدبة الوجهين غيرمغلفة، محفور على&nbsp;أحد الجانبين &quot;JP41&quot;<br />ومستوية علي الجانب الآخر.</p><p style="text-align:right">أقراص ليزينو۲۰ ملجم: لونها أصفر فاتح، دائرية، محدبة الوجهين غيرمغلفة، محفور على أحد الجانبين &#39;JP 42&#39;</p><p style="text-align:right">مستوية علي الجانب الآخر.<br />ليزينو متوفر فى أقراص ٥ ملجم، ۱۰ ملجم أو ۲۰ ملجم في عبوة تحتوى على ۳۰ قرصاً.&nbsp;<br />قد لا تكون كل العبوات مطروحة بالسوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة ،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- الھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />:(NPC) المركز الوطني للتیقظ الدوائي<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />مركز اتصال الھیئة العامة للغذاء والدواء: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />https://ade.sfda.gov.sa : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12505601 - Rev. 03/15-08-2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lisino 20 mg tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains Lisinopril dihydrate equivalent to 20 mg Lisinopril.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Light yellow round about 8.0mm biconvex uncoated tablets engraved with "JP 42" on one side and
plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension<br />Treatment of hypertension.<br />Heart failure<br />Treatment of symptomatic heart failure.<br />Acute myocardial infarction<br />Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute<br />myocardial infarction.<br />Renal complications of diabetes mellitus<br />Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient<br />nephropathy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lisino should be administered orally in a single daily dose. As with all other medication taken once<br />daily, Lisino should be taken at approximately the same time each day. The absorption of Lisino<br />tablets is not affected by food.<br />The dose should be individualised according to patient profile and blood pressure response.<br />Hypertension<br />Lisino may be used as monotherapy or in combination with other classes of antihypertensive<br />therapy.</p><p>Starting dose<br />In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a<br />strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension,<br />salt and /or volume depletion, cardiac decompensation, or severe hypertension) may experience an<br />excessive blood pressure fall following the initial dose. A starting dose of 2.5-5 mg is<br />recommended in such patients and the initiation of treatment should take place under medical<br />supervision. A lower starting dose is required in the presence of renal impairment.<br />Maintenance dose<br />The usual effective maintenance dosage is 20 mg administered in a single daily dose. In general, if<br />the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a certain dose level,<br />the dose can be further increased. The maximum dose used in long-term, controlled clinical trials<br />was 80 mg/day.<br />Diuretic-treated patients<br />Symptomatic hypotension may occur following initiation of therapy with Lisino. This is more<br />likely in patients who are being treated currently with diuretics. Caution is recommended therefore,<br />since these patients may be volume and/or salt depleted. If possible, the diuretic should be<br />discontinued 2 to 3 days before beginning therapy with Lisino. In hypertensive patients in whom<br />the diuretic cannot be discontinued, therapy with Lisino should be initiated with a 5 mg dose.<br />Renal function and serum potassium should be monitored. The subsequent dosage of Lisino should<br />be adjusted according to blood pressure response. If required, diuretic therapy may be resumed.<br />Dosage adjustment in renal impairment<br />Dosage in patients with renal impairment should be based on creatinine clearance as outlined in<br />Table 1 below.<br />Table 1 Dosage adjustment in renal impairment<br />Creatinine Clearance (ml/min) Starting Dose (mg/day)<br />Less than 10 ml/min (including patients on dialysis) 2.5 mg*<br />10-30 ml/min 2.5-5 mg<br />31-80 ml/min 5-10 mg<br />* Dosage and/or frequency of administration should be adjusted depending on the blood pressure<br />response.</p><p>The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg<br />daily.<br />Use in hypertensive paediatric patients aged 6&ndash;16 years<br />The recommended initial dose is 2.5 mg once daily in patients 20 to &lt;50 kg, and 5 mg once daily in<br />patients &ge;50 kg. The dosage should be individually adjusted to a maximum of 20 mg daily in<br />patients weighing 20 to &lt;50 kg, and 40 mg in patients &ge;50 kg. Doses above 0.61 mg/kg (or in<br />excess of 40 mg) have not been studied in paediatric patients.<br />In children with decreased renal function, a lower starting dose or increased dosing interval should<br />be considered.<br />Heart failure<br />In patients with symptomatic heart failure, Lisino should be used as adjunctive therapy to diuretics<br />and, where appropriate, digitalis or beta-blockers. Lisino may be initiated at a starting dose of 2.5<br />mg once a day, which should be administered under medical supervision to determine the initial<br />effect on the blood pressure. The dose of Lisino should be increased:<br />&bull; By increments of no greater than 10 mg<br />&bull; At intervals of no less than 2 weeks<br />&bull; To the highest dose tolerated by the patient up to a maximum of 35 mg once daily.<br />Dose adjustment should be based on the clinical response of individual patients.<br />Patients at high risk of symptomatic hypotension, e.g. patients with salt depletion with or without<br />hyponatraemia, patients with hypovolaemia or patients who have been receiving vigorous diuretic<br />therapy should have these conditions corrected, if possible, prior to therapy with Lisino. Renal<br />function and serum potassium should be monitored.<br />Posology in Acute myocardial infarction<br />Patients should receive, as appropriate, the standard recommended treatments such as<br />thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may be<br />used together with Lisino.<br />Starting dose (first 3 days after infarction)<br />Treatment with Lisino may be started within 24 hours of the onset of symptoms. Treatment should<br />not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of Lisino is 5 mg<br />given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily.</p><p>Patients with a low systolic blood pressure (120 mm Hg or less) when treatment is started or during<br />the first 3 days after the infarction should be given a lower dose - 2.5 mg orally (see section 4.4).<br />In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Lisino dosage should be<br />adjusted according to the patient&#39;s creatinine clearance .<br />Maintenance dose<br />The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less than<br />or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary reductions<br />to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less than 90 mm Hg<br />for more than 1 hour) Lisino should be withdrawn.<br />Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients who<br />develop symptoms of heart failure should continue with Lisino.<br />Renal complications of diabetes mellitus<br />In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 10 mg<br />Lisino once daily which can be increased to 20 mg once daily, if necessary, to achieve a sitting<br />diastolic blood pressure below 90 mm Hg.<br />In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Lisino dosage should be<br />adjusted according to the patient&#39;s creatinine clearance .<br />Paediatric population<br />There is limited efficacy and safety experience in hypertensive children &gt;6 years old, but no<br />experience in other indications (see section 5.1). Lisino is not recommended in children in other<br />indications than hypertension.<br />Lisino is not recommended in children below the age of 6, or in children with severe renal<br />impairment (GFR &lt; 30ml/min/1.73m2).<br />Older people<br />In clinical studies, there was no age-related change in the efficacy or safety profile of the drug.<br />When advanced age is associated with decrease in renal function, however, the guidelines set out<br />in Table 1 should be used to determine the starting dose of Lisino. Thereafter, the dosage should be<br />adjusted according to the blood pressure response.</p><p>Use in kidney transplant patients<br />There is no experience regarding the administration of Lisino in patients with recent kidney<br />transplantation. Treatment with Lisino is therefore not recommended.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to Lisino, to any of the excipients listed in section 6.1 or any other angiotensin
converting enzyme (ACE) inhibitor
• History of angioedema associated with previous ACE inhibitor therapy
• Hereditary or idiopathic angioedema
• Second and third trimesters of pregnancy.
• The concomitant use of Lisino with aliskiren-containing products is contraindicated in patients
with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic hypotension<br />Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In hypertensive<br />patients receiving Lisino, hypotension is more likely to occur if the patient has been volumedepleted,<br />e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or has<br />severe renin-dependent hypertension . In patients with heart failure, with or without associated<br />renal insufficiency, symptomatic hypotension has been observed.<br />This is most likely to occur in those patients with more severe degrees of heart failure, as reflected<br />by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In<br />patients at increased risk of symptomatic hypotension, initiation of therapy and dose adjustment<br />should be closely monitored. Similar considerations apply to patients with ischaemic heart or<br />cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial<br />infarction or cerebrovascular accident.<br />If hypotension occurs, the patient should be placed in the supine position and, if necessary, should<br />receive an intravenous infusion of normal saline. A transient hypotensive response is not a&nbsp;contraindication</p><p>to further doses, which can be given usually without difficulty once the blood<br />pressure has increased after volume expansion.<br />In some patients with heart failure who have normal or low blood pressure, additional lowering of<br />systemic blood pressure may occur with Lisino. This effect is anticipated and is not usually a<br />reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose or<br />discontinuation of Lisino may be necessary.<br />Hypotension in acute myocardial infarction<br />Treatment with Lisino must not be initiated in acute myocardial infarction patients who are at risk<br />of further serious haemodynamic deterioration after treatment with a vasodilator. These are<br />patients with systolic blood pressure of 100 mm Hg or lower, or those in cardiogenic shock.<br />During the first 3 days following the infarction, the dose should be reduced if the systolic blood<br />pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg or temporarily to<br />2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension persists (systolic blood<br />pressure less than 90 mm Hg for more than 1 hour) then Lisino should be withdrawn.<br />Aortic and mitral valve stenosis / hypertrophic cardiomyopathy<br />As with other ACE inhibitors, Lisino should be given with caution to patients with mitral valve<br />stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic<br />cardiomyopathy.<br />Renal function impairment<br />In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Lisino dosage should<br />be adjusted according to the patient&#39;s creatinine clearance , and then as a function of the patient&#39;s<br />response to treatment. Routine monitoring of potassium and creatinine is part of normal medical<br />practice for these patients.<br />In patients with heart failure, hypotension following the initiation of therapy with ACE inhibitors<br />may lead to some further impairment in renal function. Acute renal failure, usually reversible, has<br />been reported in this situation.</p><p>In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary<br />kidney, who have been treated with angiotensin-converting enzyme inhibitors, increases in blood<br />urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen.<br />This is especially likely in patients with renal insufficiency. If renovascular hypertension is also<br />present there is an increased risk of severe hypotension and renal insufficiency. In these patients,<br />treatment should be started under close medical supervision with low doses and careful dose<br />titration. Since treatment with diuretics may be a contributory factor to the above, they should be<br />discontinued and renal function should be monitored during the first weeks of Lisino therapy.<br />Some hypertensive patients with no apparent pre-existing renal vascular disease have developed<br />increases in blood urea and serum creatinine, usually minor and transient, especially when Lisino<br />has been given concomitantly with a diuretic. This is more likely to occur in patients with preexisting<br />renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or Lisino<br />may be required.<br />In acute myocardial infarction, treatment with Lisino should not be initiated in patients with<br />evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177<br />micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during<br />treatment with Lisino (serum creatinine concentration exceeding 265 micromol/l or a doubling<br />from the pre-treatment value) then the physician should consider withdrawal of Lisino.<br />Hypersensitivity/Angioedema<br />Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in<br />patients treated with angiotensin-converting enzyme inhibitors, including Lisino. This may occur<br />at any time during therapy. In such cases, Lisino should be discontinued promptly and appropriate<br />treatment and monitoring should be instituted to ensure complete resolution of symptoms prior to<br />dismissing the patients. Even in those instances where swelling of only the tongue is involved,<br />without respiratory distress, patients may require prolonged observation since treatment with<br />antihistamines and corticosteroids may not be sufficient.</p><p>Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema or<br />tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to experience<br />airway obstruction, especially those with a history of airway surgery. In such cases emergency<br />therapy should be administered promptly. This may include the administration of adrenaline<br />and/or the maintenance of a patent airway. The patient should be under close medical supervision<br />until complete and sustained resolution of symptoms has occurred.<br />Angiotensin-converting enzyme inhibitors cause a higher rate of angioedema in black patients<br />than in non-black patients.<br />Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk<br />of angioedema while receiving an ACE inhibitor.<br />Anaphylactoid reactions in haemodialysis patients<br />Anaphylactoid reactions have been reported in patients dialysed with high flux membranes (e.g.<br />AN 69) and treated concomitantly with an ACE inhibitor. In these patients, consideration should<br />be given to using a different type of dialysis membrane or different class of antihypertensive<br />agent.<br />Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis<br />Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis with<br />dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were<br />avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.<br />Desensitisation<br />Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have<br />sustained anaphylactoid reactions. In the same patients, these reactions have been avoided when<br />ACE inhibitors were temporarily withheld but they have reappeared upon inadvertent readministration<br />of the medicinal product.<br />Hepatic failure<br />Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic<br />jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this<br />syndrome is not understood. Patients receiving Lisino who develop jaundice or marked elevations<br />of hepatic enzymes should discontinue Lisino and receive appropriate medical follow-up.<br />Neutropenia/Agranulocytosis</p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients<br />receiving ACE inhibitors. In patients with normal renal function and no other complicating<br />factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after<br />discontinuation of the ACE inhibitor. Lisino should be used with extreme caution in patients with<br />collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or<br />procainamide, or a combination of these complicating factors, especially if there is pre-existing<br />impaired renal function. Some of these patients developed serious infections, which in a few<br />instances did not respond to intensive antibiotic therapy. If Lisino is used in such patients,<br />periodic monitoring of white blood cell counts is advised and patients should be instructed to<br />report any sign of infection.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including<br />acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,<br />angiotensin II receptor blockers or aliskiren is therefore not recommended .<br />If dual blockade therapy is considered absolutely necessary, this should only occur under<br />specialist supervision and subject to frequent close monitoring of renal function, electrolytes and<br />blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients<br />with diabetic nephropathy.<br />Race<br />Angiotensin-converting enzyme inhibitors cause a higher rate of angioedema in black patients<br />than in non-black patients.<br />As with other ACE inhibitors, Lisino may be less effective in lowering blood pressure in black<br />patients than in non-blacks, possibly because of a higher prevalence of low-renin states in the<br />black hypertensive population.<br />Cough<br />Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is nonproductive,<br />persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough<br />should be considered as part of the differential diagnosis of cough.</p><p>Surgery/Anaesthesia<br />In patients undergoing major surgery or during anaesthesia with agents that produce hypotension,<br />Lisino may block angiotensin II formation secondary to compensatory renin release. If<br />hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume<br />expansion.<br />Hyperkalaemia<br />Elevations in serum potassium have been observed in some patients treated with ACE inhibitors,<br />including Lisino. Patients at risk for the development of hyperkalaemia include those with renal<br />insufficiency, diabetes mellitus, or those using concomitant potassium-sparing diuretics,<br />potassium supplements or potassium-containing salt substitutes, or those patients taking other<br />drugs associated with increases in serum potassium (e.g. heparin). If concomitant use of the<br />above-mentioned agents is deemed appropriate, regular monitoring of serum potassium is<br />recommended.<br />Diabetic patients<br />In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be<br />closely monitored during the first month of treatment with an ACE inhibitor<br />Lithium<br />The combination of lithium and Lisino is generally not recommended.<br />Pregnancy<br />ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy<br />is considered essential, patients planning pregnancy should be changed to alternative antihypertensive<br />treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if<br />appropriate, alternative therapy should be started.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antihypertensive agents<br />When Lisino is combined with other antihypertensive agents (e.g. glyceryl trinitrate and other<br />nitrates, or other vasodilators), additive falls in blood pressure may occur.</p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system<br />(RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren<br />is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and<br />decreased renal function (including acute renal failure) compared to the use of a single RAASacting<br />agent .<br />Diuretics<br />When a diuretic is added to the therapy of a patient receiving Lisino the antihypertensive effect is<br />usually additive. Patients already on diuretics and especially those in whom diuretic therapy was<br />recently instituted, may occasionally experience an excessive reduction of blood pressure when<br />Lisino is added. The possibility of symptomatic hypotension with Lisino can be minimised by<br />discontinuing the diuretic prior to initiation of treatment with Lisino.<br />Potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes<br />Although in clinical trials, serum potassium usually remained within normal limits, hyperkalaemia<br />did occur in some patients. Risk factors for the development of hyperkalaemia include renal<br />insufficiency, diabetes mellitus, and concomitant use of potassium-sparing diuretics (e.g.<br />spironolactone, triamterene or amiloride), potassium supplements or potassium-containing salt<br />substitutes. The use of potassium supplements, potassium-sparing diuretics or potassiumcontaining<br />salt substitutes, particularly in patients with impaired renal function, may lead to a<br />significant increase in serum potassium. If Lisino is given with a potassium-losing diuretic,<br />diuretic-induced hypokalaemia may be ameliorated.<br />Lithium<br />Reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics<br />may increase the risk of lithium toxicity and enhance the already increased lithium toxicity with<br />ACE inhibitors. Use of Lisino with lithium is not recommended, but if the combination proves<br />necessary, careful monitoring of serum lithium levels should be performed .<br />Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid<br />&ge; 3 g/day<br />When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs<br />(i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective</p><p>NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACEinhibitors<br />and NSAIDs may lead to an increased risk of worsening of renal function, including<br />possible acute renal failure, and an increase in serum potassium, especially in patients with poor<br />pre-existing renal function. These effects are usually reversible. The combination should be<br />administered with caution, especially in the elderly. Patients should be adequately hydrated and<br />consideration should be given to monitoring renal function after initiation of concomitant therapy,<br />and periodically thereafter.<br />Gold<br />Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and<br />hypotension, which can be very severe) following injectable gold (for example, sodium<br />aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy.<br />Tricyclic antidepressants / Antipsychotics / Anaesthetics<br />Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and<br />antipsychotics with ACE inhibitors may result in further reduction of blood pressure.<br />Sympathomimetics<br />Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.<br />Antidiabetics<br />Epidemiological studies have suggested that concomitant administration of ACE inhibitors and<br />antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood<br />glucose-lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely<br />to occur during the first weeks of combined treatment and in patients with renal impairment.<br />Tissue Plasminogen Activators<br />Concomitant treatment with tissue plasminogen activators may increase the risk of angioedema.<br />Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates<br />Lisino may be used concomitantly with acetylsalicylic acid (at cardiologic doses), thrombolytics,<br />beta-blockers and/or nitrates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of<br />ACE inhibitors is contra-indicated during the second and third trimester of pregnancy.<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE<br />inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase<br />in risk cannot be excluded. Unless continued ACE inhibitors therapy is considered essential,<br />patients planning pregnancy should be changed to alternative anti-hypertensive treatments which<br />have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment<br />with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should<br />be started.<br />Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce<br />human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and<br />neonatal toxicity (renal failure, hypotension, hyperkalaemia).<br />Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy,<br />ultrasound check of renal function and skull is recommended.<br />Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension.<br />Breastfeeding<br />Because no information is available regarding the use of Lisino during breast-feeding, Lisino is not<br />recommended and alternative treatments with better established safety profiles during breastfeeding<br />are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machines it should be taken into account that occasionally<br />dizziness or tiredness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been observed and reported during treatment with Lisino<br />and other ACE inhibitors with the following frequencies: Very common (&ge; 1/10), common (&ge;<br />1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt;<br />1/10,000), not known (cannot be estimated from the available data).</p><p>Blood and the lymphatic system disorders<br />rare: decreases in haemoglobin, decreases in haematocrit<br />very rare:<br />bone marrow depression, anaemia, thrombocytopenia, leucopenia,<br />neutropenia, agranulocytosis , haemolytic anaemia, lymphadenopathy,<br />autoimmune disease.<br />Metabolism and nutrition disorders<br />very rare: hypoglycaemia.<br />Nervous system and psychiatric disorders<br />common: dizziness, headache<br />uncommon:<br />mood alterations, paraesthesia, vertigo, taste disturbance, sleep<br />disturbances, hallucinations.<br />rare: mental confusion, olfactory disturbance frequency<br />not known: depressive symptoms, syncope.<br />Cardiac and vascular disorders<br />common: orthostatic effects (including hypotension)<br />uncommon:<br />myocardial infarction or cerebrovascular accident, possibly secondary to<br />excessive hypotension in high risk patients , palpitations, tachycardia,<br />Raynaud&#39;s phenomenon.<br />Respiratory, thoracic and mediastinal disorders<br />common: cough<br />uncommon: rhinitis<br />very rare: bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia.<br />Gastrointestinal disorders<br />common: diarrhoea, vomiting<br />uncommon: nausea, abdominal pain and indigestion<br />rare: dry mouth</p><p>very rare:</p><p>pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or<br />cholestatic, jaundice and hepatic failure.<br />Skin and subcutaneous tissue disorders<br />uncommon: rash, pruritus<br />rare:<br />urticaria, alopecia, psoriasis, hypersensitivity/angioneurotic oedema:<br />angioneurotic oedema of the face, extremities, lips, tongue, glottis, and/or<br />larynx<br />very rare:<br />sweating, pemphigus, toxic epidermal necrolysis, Stevens-Johnson<br />Syndrome, erythema multiforme, cutaneous pseudolymphoma.<br />A symptom complex has been reported which may include one or more of the following: fever,<br />vasculitis, myalgia, arthralgia/arthritis, positive antinuclear antibodies (ANA), elevated red blood cell<br />sedimentation rate (ESR), eosinophilia and leucocytosis, rash, photosensitivity or other dermatological<br />manifestations may occur.<br />Renal and urinary disorders<br />common: renal dysfunction<br />rare: uraemia, acute renal failure<br />very rare: oliguria/anuria.<br />Endocrine disorders<br />rare: syndrome of inappropriate antidiuretic hormone secretion (SIADH).<br />Reproductive system and breast disorders<br />uncommon: impotence<br />rare: gynaecomastia.<br />General disorders and administration site conditions<br />uncommon: fatigue, asthenia.<br />Investigations<br />uncommon:<br />increases in blood urea, increases in serum creatinine, increases in liver<br />enzymes, hyperkalaemia</p><p>rare: increases in serum bilirubin, hyponatraemia.<br />Safety data from clinical studies suggest that lisinopril is generally well tolerated in hypertensive<br />paediatric patients, and that the safety profile in this age group is comparable to that seen in adults.<br />To report any side effects please contact National Pharmacovigilance and Drug Safety<br />Center (NPC) details below:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone: 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available for overdose in humans. Symptoms associated with overdosage of ACE<br />inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure,<br />hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.<br />The recommended treatment of overdose is intravenous infusion of normal saline solution. If<br />hypotension occurs, the patient should be placed in the shock position. If available, treatment with<br />angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is<br />recent, take measures aimed at eliminating Lisino (e.g. emesis, gastric lavage, administration of<br />absorbents and sodium sulphate). Lisino may be removed from the general circulation by<br />haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy-resistant bradycardia.<br />Vital signs, serum electrolytes and creatinine concentrations should be monitored frequently</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin-converting enzyme inhibitors, ATC code: C09A A03.<br />Mechanism of Action<br />Lisino is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that<br />catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin<br />II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in<br />decreased concentrations of angiotensin II which results in decreased vasopressor activity and</p><p>reduced aldosterone secretion. The latter decrease may result in an increase in serum potassium<br />concentration.<br />Pharmacodynamic effects<br />Whilst the mechanism through which lisinopril lowers blood pressure is believed to be primarily<br />suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in<br />patients with low renin hypertension. ACE is identical to kininase II, an enzyme that degrades<br />bradykinin. Whether increased levels of bradykinin, a potent vasodilatory peptide, play a role in<br />the therapeutic effects of lisinopril remains to be elucidated.<br />Clinical efficacy and safety<br />The effect of Lisino on mortality and morbidity in heart failure has been studied by comparing a<br />high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once daily). In a study of<br />3164 patients, with a median follow-up period of 46 months for surviving patients, high dose<br />Lisino produced a 12% risk reduction in the combined endpoint of all-cause mortality and all-cause<br />hospitalisation (p = 0.002) and an 8% risk reduction in all-cause mortality and cardiovascular<br />hospitalisation (p = 0.036) compared with low dose. Risk reductions for all-cause mortality (8%; p<br />= 0.128) and cardiovascular mortality (10%; p = 0.073) were observed. In a post-hoc analysis, the<br />number of hospitalisations for heart failure was reduced by 24% (p=0.002) in patients treated with<br />high-dose Lisino compared with low dose. Symptomatic benefits were similar in patients treated<br />with high and low doses of Lisino.<br />The results of the study showed that the overall adverse event profiles for patients treated with high<br />or low dose Lisino were similar in both nature and number. Predictable events resulting from ACE<br />inhibition, such as hypotension or altered renal function, were manageable and rarely led to<br />treatment withdrawal. Cough was less frequent in patients treated with high dose Lisino compared<br />with low dose.<br />In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Lisino and<br />glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394 patients who<br />were administered the treatment within 24 hours of an acute myocardial infarction, Lisino<br />produced a statistically significant risk reduction in mortality of 11% versus control (2p=0.03). The<br />risk reduction with glyceryl trinitrate was not significant but the combination of Lisino and<br />glyceryl trinitrate produced a significant risk reduction in mortality of 17% versus control</p><p>(2p=0.02). In the sub-groups of elderly (age &gt; 70 years) and females, pre-defined as patients at<br />high risk of mortality, significant benefit was observed for a combined endpoint of mortality and<br />cardiac function. The combined endpoint for all patients, as well as the high-risk sub-groups at 6<br />months, also showed significant benefit for those treated with Lisino or Lisino plus glyceryl<br />trinitrate for 6 weeks, indicating a prevention effect for Lisino. As would be expected from any<br />vasodilator treatment, increased incidences of hypotension and renal dysfunction were associated<br />with Lisino treatment but these were not associated with a proportional increase in mortality.<br />In a double-blind, randomised, multicentre trial which compared Lisino with a calcium channel<br />blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient nephropathy<br />characterised by microalbuminuria, Lisino 10 mg to 20 mg administered once daily for 12 months,<br />reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary albumin excretion rate by<br />40%. When compared with the calcium channel blocker, which produced a similar reduction in<br />blood pressure, those treated with Lisino showed a significantly greater reduction in urinary<br />albumin excretion rate, providing evidence that the ACE inhibitory action of Lisino reduced<br />microalbuminuria by a direct mechanism on renal tissues in addition to its blood pressure-lowering<br />effect.<br />Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect on<br />levels of glycated haemoglobin (HbA1c).<br />Renin-angiotensin system (RAS)-acting agents<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs<br />Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an<br />angiotensin II receptor blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular<br />disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA<br />NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes<br />and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as<br />compared to monotherapy was observed. Given their similar pharmacodynamic properties, these<br />results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in<br />patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease<br />Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an<br />ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and<br />chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of<br />an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically<br />more frequent in the aliskiren group than in the placebo group and adverse events and serious<br />adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more<br />frequently reported in the aliskiren group than in the placebo group.<br />Paediatric population<br />In a clinical study involving 115 paediatric patients with hypertension, aged 6&ndash;16 years, patients<br />who weighed less than 50 kg received either 0.625 mg, 2.5 mg or 20 mg of Lisino once a day, and<br />patients who weighed 50 kg or more received either 1.25 mg, 5 mg or 40 mg of Lisino once a day.<br />At the end of 2 weeks, Lisino administered once daily lowered trough blood pressure in a dosedependent<br />manner with a consistent antihypertensive efficacy demonstrated at doses greater than<br />1.25 mg.<br />This effect was confirmed in a withdrawal phase, where the diastolic pressure rose by about 9 mm<br />Hg more in patients randomised to placebo than it did in patients who were randomised to remain<br />on the middle and high doses of Lisino. The dose-dependent antihypertensive effect of Lisino was<br />consistent across several demographic subgroups: age, Tanner stage, gender, and race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.<br />Absorption<br />Following oral administration of lisinopril, peak serum concentrations occur within about 7 hours,<br />although there was a trend to a small delay in time taken to reach peak serum concentrations in<br />acute myocardial infarction patients. Based on urinary recovery, the mean extent of absorption of<br />lisinopril is approximately 25% with interpatient variability of 6-60% over the dose range studied<br />(5-80 mg). The absolute bioavailability is reduced approximately 16% in patients with heart<br />failure. Lisinopril absorption is not affected by the presence of food.</p><p>Distribution<br />Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensinconverting<br />enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain barrier<br />poorly.<br />Elimination<br />Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. On<br />multiple dosing, lisinopril has an effective half-life of accumulation of 12.6 hours. The clearance of<br />lisinopril in healthy subjects is approximately 50 ml/min. Declining serum concentrations exhibit a<br />prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase<br />probably represents saturable binding to ACE and is not proportional to dose.<br />Hepatic impairment<br />Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril absorption<br />(about 30% as determined by urinary recovery), but an increase in exposure (approximately 50%)<br />compared to healthy subjects due to decreased clearance.<br />Renal impairment<br />Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, but<br />this decrease becomes clinically important only when the glomerular filtration rate is below 30<br />ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min), mean AUC<br />was increased by 13% only, while a 4.5- fold increase in mean AUC was observed in severe renal<br />impairment (creatinine clearance 5-30 ml/min).<br />Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril<br />concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 ml/min.<br />Heart failure<br />Patients with heart failure have a greater exposure of lisinopril when compared to healthy subjects<br />(an increase in AUC on average of 125%), but based on the urinary recovery of lisinopril, there is<br />reduced absorption of approximately 16% compared to healthy subjects.<br />Paediatric population<br />The pharmacokinetic profile of lisinopril was studied in 29 paediatric hypertensive patients, aged<br />between 6 and 16 years, with a GFR above 30 ml/min/1.73m2. After doses of 0.1 to 0.2 mg/kg,</p><p>steady state peak plasma concentrations of lisinopril occurred within 6 hours, and the extent of<br />absorption based on urinary recovery was about 28%. These values are similar to those obtained<br />previously in adults.<br />AUC and Cmax values in children in this study were consistent with those observed in adults.<br />Older people<br />Older patients have higher blood levels and higher values for the area under the plasma<br />concentration-time curve (increased approximately 60%) compared with younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of general<br />pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensinconverting<br />enzyme inhibitors, as a class, have been shown to induce adverse effects on the late<br />foetal development, resulting in foetal death and congenital effects, in particular affecting the skull.<br />Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also been reported.<br />These developmental anomalies are thought to be partly due to a direct action of ACE inhibitors on<br />the foetal renin-angiotensin system and partly due to ischaemia resulting from maternal<br />hypotension and decreases in foetal-placental blood flow and oxygen/nutrients delivery to the<br />foetus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dibasic Calcium Phosphate Dihydrate<br />Mannitol<br />Pregelatinised Starch &ndash; 1500<br />Maize Starch<br />Iron Oxide Yellow<br />Dried Maize Starch<br />Colloidal Silicon Dioxide - Aerosil 200<br />Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lisino 20 mg Tablets are packed in Aluminum - PVC / PVDC blister of 10 Tablets each.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Comapny
P.O. Box 6267
Jeddah 21442
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug-2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>